Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

被引：8

作者：

Arnold, Dirk

Andre, Thierry

Bennouna, Jaafar

Sastre, Javier

Osterlund, Pia J.

Greil, Richard

Van Cutsem, Eric

Von Moos, Roger

Reyes-Rivera, Irmarie

Bendahmane, Belguendouz

Kubicka, Stefan

机构：

[1] UCCH, Hubertus Wald Tumor Ctr, Hamburg, Germany

[2] Hop St Antoine, F-75571 Paris, France

[3] Inst Cancerol Ouest Site Rene Gauducheau, Nantes, France

[4] Hosp Clin San Carlos, Madrid, Spain

[5] Univ Helsinki, Cent Hosp, Helsinki, Finland

[6] Paracelsus Med Univ Hosp Salzburg, Med Dept Hematol Med Oncol 3, Salzburg, Austria

[7] AGMT Arbeitsgemeinschaft Medikamentose Tumorthera, Salzburg, Austria

[8] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[9] Kantonsspital Graubuenden, Graubuenden, Switzerland

[10] Genentech Inc, San Francisco, CA 94080 USA

[11] Roche, Basel, Switzerland

[12] Dist Clin Reutlingen, Dept Internal Med 1, Reutlingen, Germany

来源：

关键词：

D O I：

10.1200/jco.2012.30.18_suppl.cra3503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CRA3503

引用

页数：1